表紙
市場調查報告書

關注市場分析:子宮肌瘤

Market Spotlight: Uterine Fibroids

出版商 Datamonitor Healthcare 商品編碼 603897
出版日期 內容資訊 英文 44 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
關注市場分析:子宮肌瘤 Market Spotlight: Uterine Fibroids
出版日期: 2019年12月02日內容資訊: 英文 44 Pages
簡介

全球15歲以上的女性人口的子宮肌瘤的患病人數預計從2016年的約9070萬件,至2025年增加到1億100萬件。

本報告提供全球子宮肌瘤的治療藥的市場調查,疾病的背景、概要,患病人數的十年預測,主要的治療方法,已上市藥物及藥物開發平台趨勢,授權、資產收購等企業間的主要交易趨勢,專利資訊,臨床試驗狀況等彙整資料。

要點

疾病的背景

  • 亞型

治療

  • 外科的治療
  • 藥物

流行病學

已上市藥物

  • 核准:各國

開發平台藥物

今後主要的活動

授權、資產收購等的交易

本源專利

商機

臨床試驗環境

  • 贊助商:各進展狀況
  • 贊助商:各階段
  • 近幾年的活動

文獻

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0183230

This Market Spotlight report covers the Uterine Fibroids market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals.

Key Takeaways

Datamonitor Healthcare estimates that in 2017, there were approximately 92.2 million prevalent cases of uterine fibroids worldwide in females aged 15 years and over, and forecasts that number to increase to 102.7 million prevalent cases by

2026. Lupron and relugolix, which target gonadotropin-releasing hormone receptor, and ulipristal acetate, which targets progesterone receptor, are the only approved drugs for uterine fibroids. These drugs are administered via the oral and subcutaneous routes.

Half of the industry-sponsored drugs in active clinical development for uterine fibroids are in Phase III, with one drug in the NDA/BLA phase.

Therapies in development for uterine fibroids focus on targets such as progesterone receptor, gonadotropin-releasing hormone receptor, and collagen. The majority of pipeline drugs are administered via the oral route, with one product being available in a subcutaneous formulation.

High-impact upcoming events for drugs in the uterine fibroids space comprise topline Phase III trial results and an expected meeting with the FDA for linzagolix, and an estimated PDUFA date for Orilissa.

The overall likelihood of approval of a Phase I gynecology asset is 13.3%, and the average probability a drug advances from Phase III is 60%. Drugs, on average, take 10.6 years from Phase I to approval, compared to 12.4 years in the overall obstetrics/gynecology space.

There have been 13 licensing and asset acquisition deals involving uterine fibroids drugs during 2014-19. The values have not been disclosed for any of these deals.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for uterine fibroids have been in the early and mid-phases of development, with 60% of trials in Phase I-II, and 40% in Phase III-IV.

The US has a substantial lead in the number of uterine fibroids clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.

Clinical trial activity in the uterine fibroids space is dominated by completed trials. Repros Therapeutics has the highest number of completed clinical trials for uterine fibroids, with 17 trials.

Repros Therapeutics leads industry sponsors with the highest number of clinical trials for uterine fibroids, followed by Takeda

TABLE OF CONTENTS

CONTENTS

6 OVERVIEW

7 KEY TAKEAWAYS

8 DISEASE BACKGROUND

8 Subtypes

9 TREATMENT

9 Surgery

9 Medical agents

10 EPIDEMIOLOGY

13 MARKETED DRUGS

15 PIPELINE DRUGS

19 RECENT EVENTS AND ANALYST OPINION

19 Relugolix for Uterine Fibroids (July 23, 2019)

20 Multiple Drugs for Uterine Fibroids (June 25, 2019)

21 Relugolix for Uterine Fibroids (May 14, 2019)

23 Vilaprisan for Uterine Fibroids (December 05, 2018)

24 Ekobi 500 Embolization Microspheres for Uterine Fibroids (November 20, 2018)

26 Orilissa for Uterine Fibroids (August 22, 2018)

28 Ulipristal Acetate for Uterine Fibroids (August 21, 2018)

29 Ulipristal Acetate for Uterine Fibroids (May 18, 2018)

31 KEY UPCOMING EVENTS

32 KEY REGULATORY EVENTS

32 AbbVie Revs Up The Race To Market In Uterine Fibroids

32 Myovant Plans Q4 Uterine Fibroid Drug Filing In A Showdown With AbbVie

33 PROBABILITY OF SUCCESS

34 LICENSING AND ASSET ACQUISITION DEALS

34 Deals Shaping The Medical Industry, August 2019

34 QXMedical Gets Exclusive Rights To University of Minnesota Bioresorbable Technology

36 PARENT PATENTS

37 REVENUE OPPORTUNITY

38 CLINICAL TRIAL LANDSCAPE

39 Sponsors by status

40 Sponsors by phase

41 Recent events

42 BIBLIOGRAPHY

42 Prescription information

43 APPENDIX

LIST OF FIGURES

  • 12 Figure 1: Trends in prevalent cases of uterine fibroids, 2017-26
  • 15 Figure 2: Overview of pipeline drugs for uterine fibroids in the US
  • 15 Figure 3: Pipeline drugs for uterine fibroids, by company
  • 16 Figure 4: Pipeline drugs for uterine fibroids, by drug type
  • 16 Figure 5: Pipeline drugs for uterine fibroids, by classification
  • 20 Figure 6: Relugolix for Uterine Fibroids (July 23, 2019): Phase III - LIBERTY 2
  • 23 Figure 7: Relugolix for Uterine Fibroids (May 14, 2019): Phase III - LIBERTY 1
  • 28 Figure 8: Orilissa for Uterine Fibroids (August 22, 2018): Phase III - ELARIS UF-EXTEND
  • 31 Figure 9: Key upcoming events in uterine fibroids
  • 33 Figure 10: Probability of success in the uterine fibroids pipeline
  • 34 Figure 11: Licensing and asset acquisition deals in uterine fibroids, 2014-19
  • 36 Figure 12: Parent patents in uterine fibroids
  • 38 Figure 13: Clinical trials in uterine fibroids
  • 38 Figure 14: Top 10 drugs for clinical trials in uterine fibroids
  • 39 Figure 15: Top 10 companies for clinical trials in uterine fibroids
  • 39 Figure 16: Trial locations in uterine fibroids
  • 40 Figure 17: Uterine fibroids trials status
  • 41 Figure 18: Uterine fibroids trials sponsors, by phase

LIST OF TABLES

  • 11 Table 1: Prevalent cases of uterine fibroids, 2017-26
  • 14 Table 2: Marketed drugs for uterine fibroids
  • 17 Table 3: Pipeline drugs for uterine fibroids in the US
  • 19 Table 4: Relugolix for Uterine Fibroids (July 23, 2019)
  • 21 Table 5: Multiple Drugs for Uterine Fibroids (June 25, 2019)
  • 22 Table 6: Relugolix for Uterine Fibroids (May 14, 2019)
  • 24 Table 7: Vilaprisan for Uterine Fibroids (December 05, 2018)
  • 25 Table 8: Ekobi 500 Embolization Microspheres for Uterine Fibroids (November 20, 2018)
  • 27 Table 9: Orilissa for Uterine Fibroids (August 22, 2018)
  • 28 Table 10: Ulipristal Acetate for Uterine Fibroids (August 21, 2018)
  • 29 Table 11: Ulipristal Acetate for Uterine Fibroids (May 18, 2018)
  • 37 Table 12: Historical global sales, by drug ($m), 2014-18
  • 37 Table 13: Forecasted global sales, by drug ($m), 2019-23
Back to Top